ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01CE01 | B | Topotecan HCl - 4mg | 8862 | 129916/1 | HYCAMTIN IV | 4mg | 5 | Injectable lyophilised powder for solution | Infusion | Khalil Fattal & Fils S.A.L. | GlaxoSmithKline Manufacturing SpA | Italy | 52,580,031 L.L | 10.71 | E1 | Novartis Pharma AG | Switzerland | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01CE01 | B | Topotecan HCl - 4mg | 11520 | 4923/1 | HYCAMTIN IV | 4mg | 5 | Injectable lyophilised powder for solution | Infusion | Khalil Fattal & Fils S.A.L. | GlaxoSmithKline Manufacturing SpA | Italy | 52,580,031 L.L | 10.71 | E1 | Sandoz Pharmaceuticals AG | Switzerland | 2/5/2024 | 0 |